Trial reportYonsei medical journal2005
Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study.
Trial report in Yonsei medical journal, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01722578 (Efficacy of Intravenous 'L-ornithine L-aspartate' in Reversal of Overt Acute Hepatic Encephalopathy in Patients With Liver Cirrhosis), which is not on this map. Cited by 38 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy of Intravenous 'L-ornithine L-aspartate' in Reversal of Overt Acute Hepatic Encephalopathy in Patients With Liver Cirrhosis: a Prospective, Randomized, Double-blind, Placebo Controlled Trial
Who cites it
38 citing papers in PubMed, 5 syntheses or guidelines pooled it, 121 citations in OpenAlex.
- Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis.The Cochrane database of systematic reviews · 2023Pooled it
- KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications.Clinical and molecular hepatology · 2020Guideline
- Revision and update on clinical practice guideline for liver cirrhosis.The Korean journal of hepatology · 2012Guideline
- Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis.World journal of gastroenterology · 2012Pooled it
- Is oral L-acyl-carnitine an effective therapy for hepatic encephalopathy? Review of the literature.Digestive diseases and sciences · 2008Pooled it
- Rifaximin Plus Probiotics Reshape Gut Microbiota, Serum Propionate, and Mucosal Immunity in Cirrhosis-Related Hepatic Encephalopathy Microbiota-Immune Remodeling in HE.Canadian journal of gastroenterology & hepatology · 2026Trial
- Erythromycin versus neomycin in the treatment of hepatic encephalopathy in cirrhosis: a randomized double-blind study.BMC gastroenterology · 2013Trial
- Minimal Hepatic Encephalopathy: A Narrative Review.Cureus · 2026Review
- Article
- Therapeutic Duel of Rifaximin Versus Lactulose in Hepatic Encephalopathy: A Systematic Review.Cureus · 2025Review
- Evaluation of a protocol for rifaximin discontinuation in critically ill patients with liver disease receiving broad-spectrum antibiotic therapy.World journal of hepatology · 2023Article
- Probiotics combined with rifaximin influence the neurometabolic changes in a rat model of type C HE.Scientific reports · 2021Article
- Efficacy and Safety of Rifaximin Versus Placebo or Other Active Drugs in Critical ill Patients With Hepatic Encephalopathy.Frontiers in pharmacology · 2021Review
- Lessons from "real life experience" of rifaximin use in the management of recurrent hepatic encephalopathy.World journal of hepatology · 2020Article
- Use Of Quantitative Modelling To Elucidate The Roles Of The Liver, Gut, Kidney, And Muscle In Ammonia Homeostasis And How Lactulose And Rifaximin Alter This Homeostasis.International journal of general medicine · 2019Review
- Biological Activities of Lactose-Derived Prebiotics and Symbiotic with Probiotics on Gastrointestinal System.Medicina (Kaunas, Lithuania) · 2018Review
- A model of blood-ammonia homeostasis based on a quantitative analysis of nitrogen metabolism in the multiple organs involved in the production, catabolism, and excretion of ammonia in humans.Clinical and experimental gastroenterology · 2018Review
- Cost-effectiveness analysis of rifaximin-α administration for the reduction of episodes of overt hepatic encephalopathy in recurrence compared with standard treatment in France.Therapeutic advances in gastroenterology · 2016Article
- Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications.World journal of gastroenterology · 2015Review
- Covert and Overt Hepatic Encephalopathy: Diagnosis and Management.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rifaximin has been reported to be effective for the treatment of hepatic encephalopathy (HE) in Europe. However, it is unknown whether Rifaximin is effective for the treatment of HE in Koreans, therefore we conducted a open-label prospective randomized study to evaluate the efficacy of rifaximin versus lactulose in Korean patients. Fifty-four patients with liver cirrhosis and hepatic encephalopathy were enrolled. Thirty-two patients were randomized to receive rifaximin and 22 to receive lactulose both over a 7-day periods. Before and at the end of treatment, gradation of blood ammonia, flapping tremor, mental status, number connection test (NCT) were performed and estimation of HE indexes determined. Both rifaximin and lactulose were effective in the majority of patients (84.4% and 95.4%, respectively, p = 0.315). Blood NH3, flapping tremor, mental status, and NCT was significantly improved by rifaximin and lactulose, and the post- treatment levels of these measures were similar for the rifaximin and lactulose-treated groups, as was the HE index (rifaximin group (10.0 --> 4.2, p = 0.000); lactulose group (11.3 --> 5.0, p = 0.000)). One patient treated with rifaximin complained of abdominal pain, which was easily controlled. There was no episode of renal function impairment in either treatment group. Rifaximin proved to be as safe and as effective as lactulose for the treatment of Korean patients with hepatic encephalopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.